We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2),  influenza viruses, noroviruses and hepatitis C viruses.  We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

We are leveraging our core competencies and decade of experience in antiviral therapeutics to combat pandemic and seasonal influenza and the global COVID-19 health crisis. Given the growing global need for an effective, safe antiviral treatment, we are advancing multiple antiviral therapeutic candidates as quickly and efficiently as possible, while also advancing the discovery and development of antiviral compounds for other high-value indications.

Targeted Solutions for Viral Diseases

Novel antiviral therapeutics for the treatment of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.

View Product Pipeline

About Us

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

Learn More

Technology

We utilize unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.

Learn More

Development Programs

Our development programs include a wide variety of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.

Learn More
Program Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3
Influenza A CC-42344 oral PB2 Inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase complete
Phase 2b Phase complete
Phase 3 Phase complete
Influenza A/B

In collaboration with

Collaboration
Influenza A/B Inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase complete
Phase 2b Phase complete
Phase 3 Phase complete
Influenza A CC-42344 Inhaled PB2 inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase complete
Phase 2b Phase complete
Phase 3 Phase complete
COVID-19 CDI-988 Oral Protease Inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase complete
Phase 2b Phase complete
Phase 3 Phase complete
COVID-19 (Licensed) CDI-45205 Protease Inhibitor
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started
COVID-19 Replication Inhibitors
Discovery Phase in progress
Preclinical Phase not started
Phase 1 Phase not started
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started
Norovirus Gastroenteritis Replication and Protease Inhibitors
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started

Investor Presentation

View our latest Corporate Presentation

View Presentation View Fact Sheet